Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - General Information About Ovarian Low Malignant Potential Tumors
Ovarian low malignant potential tumor is a disease in which abnormal cells form in the tissue covering the ovary. Ovarian low malignant potential tumors have abnormalcells that may become cancer,but usually do not. This disease usually remains in the ovary. When disease is found in one ovary,the other ovary should also be checked carefully for signs of disease. The ovaries are a pair of ...
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (07 / 30 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.SignificanceUpdated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 1).This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about ovarian cancer prevention. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Recurrent or Persistent Ovarian Epithelial Cancer
Recurrent ovarian epithelial cancer is cancer that has recurred (come back) after it has been treated. Persistent cancer is cancer that does not go away with treatment.
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Ovarian Cancer Prevention
Avoiding risk factors and increasing protective factors may help prevent cancer.Avoiding cancer risk factors may help prevent certain cancers. Risk factors include smoking, being overweight, and not getting enough exercise. Increasing protective factors such as quitting smoking, eating a healthy diet, and exercising may also help prevent some cancers. Talk to your doctor or other health care professional about how you might lower your risk of cancer.The following risk factors may increase the risk of ovarian cancer:Family history of ovarian cancerA woman whose mother or sister had ovarian cancer has an increased risk of ovarian cancer. A woman with two or more relatives with ovarian cancer also has an increased risk of ovarian cancer. Inherited riskThe risk of ovarian cancer is increased in women who have inherited certain changes in the following genes:BRCA1 or BRCA2 genes.Genes that are linked to hereditary nonpolyposis colorectal cancer (HNPCC; Lynch syndrome).Hormone replacement
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000062760-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Cancer Screening
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Stage IV Ovarian Germ Cell Tumors
DysgerminomasStandard treatment options:Total abdominal hysterectomy and bilateral salpingo-oophorectomy with adjuvant chemotherapy.Unilateral salpingo-oophorectomy with adjuvant chemotherapy.For patients with stage IV dysgerminoma, total abdominal hysterectomy and bilateral salpingo-oophorectomy is recommended with removal of as much gross tumor in the abdomen and pelvis as can be done safely without resection of portions of the urinary tract or large segments of small or large bowel, although unilateral salpingo-oophorectomy should be considered in patients who wish to preserve fertility.[1,2] Chemotherapy with bleomycin/etoposide/cisplatin (BEP) can cure the majority of such patients. Stage IV dysgerminoma is not treated with radiation therapy, but rather with chemotherapy, preferably with three to four courses of cisplatin-containing combination chemotherapy such as BEP. A second-look operation following treatment is rarely beneficial. (Refer to the PDQ summary on Sexuality and
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Treatment Option Overview
Standard treatment options for patients with ovarian germ cell tumors include:Surgery.Chemotherapy.Radiation therapy.Patients may be treated with unilateral salpingo-oophorectomy or total abdominal hysterectomy and bilateral salpingo-oophorectomy.All patients except those with stage I, grade I immature teratoma and stage IA dysgerminoma require postoperative chemotherapy. With platinum-based combination chemotherapy, the prognosis for patients with endodermal sinus tumors, immature teratomas, embryonal carcinomas, choriocarcinomas, and mixed tumors containing one or more of these elements has improved dramatically. As new and more effective drugs are developed, many of these patients will be candidates for newer clinical trials.Treatment options under clinical evaluation for patients with ovarian germ cell tumors include:High-dose chemotherapy with bone marrow transplant.New treatment options.References: Gershenson DM, Morris M, Cangir A, et al.: Treatment of malignant germ cell
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Early-Stage Ovarian Low Malignant Potential Tumors
The value of complete staging has not been demonstrated for early-stage cases, but the opposite ovary should be carefully evaluated for evidence of bilateral disease. Although the impact of surgical staging on therapeutic management is not defined, in a study, 7 of 27 patients with presumed localized disease were upstaged following complete surgical staging. In two other studies, 16% and 18% of patients with presumed localized tumors of low malignant potential were upstaged as a result of a staging laparotomy.[2,3] In one of these studies, the yield for serous tumors was 30.8% compared with 0% for mucinous tumors. In another study, patients with localized intraperitoneal disease and negative lymph nodes had a low incidence of recurrence (5%), whereas patients with localized intraperitoneal disease and positive lymph nodes had a statistically significantly higher incidence of recurrence (50%).In early-stage disease (stage I or II), no additional treatment is indicated for a